Wockhardt Recalls Zonisamide Capsules Due to Complaint Investigation Failures
Wockhardt USA is recalling 84,542 bottles of Zonisamide 50 mg capsules because the firm did not adequately investigate customer complaints.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II due to CGMP deviations regarding complaint investigation. As no specific adverse health consequences or illnesses are reported in the source text, and the hazard is procedural rather than a direct contamination or defect causing immediate harm, it aligns with the 'Moderate' severity criteria for minor labeling or procedural errors.
Plain-English summary
Wockhardt USA LLC is recalling 84,542 bottles of Zonisamide Capsules, 50 mg, packaged in 100-count bottles. The product is prescription-only and was distributed nationwide, including Puerto Rico. The capsules were manufactured by Wockhardt Limited in Mumbai, India, and distributed by Wockhardt USA LLC in Parsippany, New Jersey.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. Specifically, the firm failed to adequately investigate customer complaints. The affected lots have expiration dates ranging from April 30, 2015, to August 31, 2016.
Consumers and healthcare providers should stop using the recalled product and contact their pharmacist or healthcare provider for guidance on obtaining a replacement. The recall is classified as FDA Class II, indicating a reasonable probability that use of the product may cause temporary or medically reversible adverse health consequences.
The recalled product
- Product
- Zonisamide Capsules, 50 mg Capsules, Packaged in 100 Count Bottles, Rx Only. Manufactured by: Wockhardt Limited, Mumbai, India. Distributed by: Wockhardt USA LLC 20 Waterview Blvd. Parsippany, NJ 07054 USA. NDC: 64679-0946-01.
- Manufacturer
- Wockhardt Usa Inc.
- Category
- Drug — Anticonvulsant
- Affected units
- 84,542
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot #: LM10769
- Expiry: 4/30/2015
- Lot #: LM10770
- Lot #: LM10771
- Lot #: LM10875
- Expiry: 5/31/2015
- Lot #: LM10876
- Lot #: LM11145
- Expiry: 6/30/2015
- Lot #: LM11174
- Lot #: LM11175
- Lot #: LM11226
- Expiry: 7/31/2015
- Lot #: LM11227
- Lot #: LM11289
- Lot #: LM11290
- Lot #: LM11544
- Expiry: 8/31/2015
- Lot #: LM11545
- Lot #: LM11671
Distribution
Part of a larger recall action
This product is one of 35 recalled by Wockhardt Usa Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 35 products in this recall →Related recalls
Same manufacturer · Wockhardt Usa Inc.
See all →- LowWockhardt Recalls Enalapril Maleate Tablets Due to Impurity Failures
FDA (Drugs) · 2017-11-01
- ModerateWockhardt Recalls Lisinopril Tablets Due to Inadequate Complaint Investigations
FDA (Drugs) · 2015-08-26
- ModerateWockhardt Recalls Lisinopril Tablets Due to Inadequate Complaint Investigations
FDA (Drugs) · 2015-08-26
- ModerateWockhardt Recalls Azithromycin Tablets Due to Complaint Investigation Failures
FDA (Drugs) · 2015-07-29
- ModerateWockhardt Recalls Zolpidem Tartrate Tablets Due to Complaint Investigation Failures
FDA (Drugs) · 2015-07-29
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- SevereShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19